HC Wainwright Has Negative Outlook for LRMR FY2025 Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Research analysts at HC Wainwright reduced their FY2025 EPS estimates for shares of Larimar Therapeutics in a research note issued to investors on Monday, December 16th. HC Wainwright analyst E. White now anticipates that the company will earn ($1.77) per share for the year, down from their previous estimate of ($1.57). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Larimar Therapeutics’ FY2026 earnings at ($1.99) EPS.

A number of other analysts also recently commented on the company. Robert W. Baird started coverage on Larimar Therapeutics in a research report on Wednesday, September 4th. They set an “outperform” rating and a $16.00 price target for the company. Baird R W upgraded shares of Larimar Therapeutics to a “strong-buy” rating in a report on Wednesday, September 4th. Oppenheimer began coverage on shares of Larimar Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $26.00 target price on the stock. Wedbush began coverage on shares of Larimar Therapeutics in a research note on Thursday, October 3rd. They set an “outperform” rating and a $22.00 price target for the company. Finally, William Blair reissued an “outperform” rating on shares of Larimar Therapeutics in a report on Tuesday, November 19th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $20.43.

Larimar Therapeutics Trading Down 3.1 %

Shares of LRMR traded down $0.13 during trading hours on Thursday, reaching $4.03. 240,308 shares of the stock traded hands, compared to its average volume of 621,062. Larimar Therapeutics has a 52 week low of $3.01 and a 52 week high of $13.68. The stock has a fifty day simple moving average of $7.03 and a 200 day simple moving average of $7.68. The company has a market cap of $257.14 million, a price-to-earnings ratio of -3.50 and a beta of 0.86.

Larimar Therapeutics (NASDAQ:LRMR) last released its earnings results on Wednesday, October 30th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.13. During the same quarter last year, the company posted ($0.21) EPS.

Institutional Trading of Larimar Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of LRMR. Quarry LP grew its holdings in shares of Larimar Therapeutics by 966.7% during the 2nd quarter. Quarry LP now owns 8,000 shares of the company’s stock valued at $58,000 after purchasing an additional 7,250 shares during the last quarter. Quest Partners LLC grew its stake in shares of Larimar Therapeutics by 171.1% during the third quarter. Quest Partners LLC now owns 9,183 shares of the company’s stock valued at $60,000 after buying an additional 5,796 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Larimar Therapeutics during the third quarter valued at about $71,000. Intech Investment Management LLC purchased a new position in shares of Larimar Therapeutics in the third quarter worth about $85,000. Finally, Thoroughbred Financial Services LLC bought a new stake in shares of Larimar Therapeutics in the 2nd quarter valued at about $94,000. Hedge funds and other institutional investors own 91.92% of the company’s stock.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.